
New Therapies for Patients With Type 2 Diabetes
Diabetes mellitus is a growing health problem in the United States. According to a recent CDC report, as of 2015, 30.3 million Americans (9.4% of the US population) have diabetes. Of these, 90% to 95% are diagnosed with type 2 diabetes (T2D). This number will likely continue to grow, because an estimated 84.1 million Americans have pre-diabetes, putting them at increased risk of T2D development.1 The manufacturers of the novel combination therapies that enter the market each year hope to simplify medication regimens for patients with T2D and to improve their adherence. Select combination products that were approved in the last few years for T2D are listed in Table 1.2-9
Many patients with T2D will require insulin therapy; however, these patients are also likely to develop insulin resistance over time. Due to insulin resistance and decreased endogenous insulin secretion, patients may require higher insulin doses and an increased number of insulin injections.10 As the needed insulin dosage increases, so, typically, does the volume of injected insulin. Because larger volumes of insulin can lead to painful injections and unpredictable insulin absorption,10 concentrated insulins have become more prominent in clinical practice. Several different insulin formulations have become available in the last few years. Two new insulin/glucagon-like peptide-1 receptor agonist (GLP-1 RA) combination products have also recently entered the market.
INSULIN
Four different concentrated insulins are currently indicated for patients with T2D. These concentrated insulins are available in the pen f
Continue
reading